Amir A. Al-Khami, Ph.D. Dr. Al-Khami completed PhD in tumor immunology under a program between Tanta University Egypt and The Medical University of South Carolina in 2009. His dissertation established some of the mechanisms by which lymphodepletion enhances adoptive T cell therapy of cancer. Following PhD, Dr. Al-Khami accepted a postdoctoral fellowship in the laboratory of Dr. Shikhar Mehrotra at The Medical University of South Carolina in 2010. He studied the activation-induced cell death in tumor-reactive CD8+ T cell subsets, in addition to a novel transgenic mouse model of cancer, which was developed in the laboratory using a human tyrosinase epitope-reactive T cell receptor. In 2012, Dr. Al-Khami accepted a second postdoctoral fellowship in the laboratory of Dr. Augusto Ochoa at LSU Health Sciences Center to study the role of energy metabolic reprogramming in tumor-associated myeloid-derived suppressor cells.
Dr. Al-Khami'slong-term goal of research is to develop strategies that elicit tumor-specific T cell responses that will be robust and long-lived to generate durable tumor eradication. A current focus area isthe therapeutic targeting of myeloid-derived suppressor cells (MDSC) as a means to restore T cell antitumor immunity.